According to Gram Research analysis, parathyroid hormone (PTH) activates a previously unknown bone remodeling process that creates tunnel-like structures inside bones, increasing internal porosity up to 36-fold over 30 months of treatment. This internal remodeling allows bones to repair damage deep inside their structure that surface-level bone repair cannot reach. The process is reversible—when patients stopped PTH treatment, their bones returned to normal remodeling patterns, proving PTH directly controls this mechanism.
Scientists have discovered a previously unknown way that bones remodel themselves from the inside, triggered by parathyroid hormone (PTH). In a study of patients with low parathyroid hormone levels, researchers found that PTH treatment caused bones to develop tunnel-like structures inside their framework, increasing internal porosity up to 36-fold over 30 months. This internal remodeling appears to help remove old and damaged bone that surface-level bone repair can’t reach. When patients stopped PTH treatment, their bones returned to normal remodeling patterns, suggesting this process is reversible and controlled by hormone levels.
Key Statistics
A 2026 clinical trial published in the Journal of Bone and Mineral Research found that parathyroid hormone treatment increased internal bone porosity 18-fold after 6 months and 36-fold after 30 months compared to standard treatment alone in patients with hypoparathyroidism.
In patients receiving PTH treatment for 6 months, 69.1% of internal bone pores showed simultaneous bone breakdown and formation, compared to 0.0% in patients on standard treatment, according to bone biopsy analysis in the 2026 study.
When patients discontinued PTH treatment, internal bone remodeling normalized to levels similar to conventional therapy alone, demonstrating the reversibility of this hormone-driven process in a 24-month follow-up study.
Active vitamin D supplementation showed a negative correlation with PTH-induced internal bone remodeling, suggesting that vitamin D may suppress this tunneling process in patients with hypoparathyroidism.
The Quick Take
- What they studied: How parathyroid hormone (PTH) affects the way bones rebuild themselves, specifically looking at changes inside the bone structure rather than just on the surface
- Who participated: Patients with hypoparathyroidism (a condition where the body doesn’t make enough parathyroid hormone) who received either PTH injections or placebo for 6 months, with some continuing for up to 30 months
- Key finding: PTH treatment caused bones to develop internal tunnel networks that increased porosity (tiny holes) by 18 times after 6 months and 36 times after 30 months, compared to patients on standard treatment alone
- What it means for you: This discovery reveals a new way bones naturally repair themselves that doctors didn’t fully understand before. It may eventually help improve treatments for bone diseases, though more research is needed to understand if this process is beneficial or harmful in different situations
The Research Details
Researchers studied bone samples from patients with hypoparathyroidism (a rare condition where the body produces too little parathyroid hormone). Half the patients received daily PTH injections for 6 months while continuing their regular treatment, and the other half received placebo injections. Some patients continued PTH treatment for up to 30 months total. Scientists examined bone biopsies (tiny bone samples) under microscopes to measure changes in bone structure, counting how many tunnel-like structures formed inside the bones and tracking whether new bone was being made or old bone was being removed.
The researchers used advanced imaging technology called synchrotron radiation microscopy to watch these changes happen in real time using rabbit bone samples. They also used computer models to understand how the bone’s internal stress patterns might drive these tunnel formations. This combination of human patient data and animal model studies allowed them to both confirm the findings and understand the mechanics behind them.
The study was rigorous because it included a control group (patients on placebo), measured specific structural changes in bone samples, and tracked what happened when patients stopped taking PTH to see if the changes reversed.
Understanding how bones remodel themselves from the inside is important because it reveals a completely different mechanism than what doctors previously focused on. Surface-level bone remodeling (where bone is removed and rebuilt on the outer edges) can’t reach the oldest and most damaged bone deep inside the structure. This internal tunneling process appears to be nature’s way of accessing and replacing those hard-to-reach damaged areas. This discovery could eventually lead to better treatments for osteoporosis, kidney disease, and other conditions affecting bone health.
This study has several strengths: it included a randomized controlled trial design (the gold standard for medical research), used objective measurements of bone structure, included both short-term (6 months) and long-term (30 months) follow-up, and confirmed findings using animal models. The study also showed that changes reversed when treatment stopped, strengthening the evidence that PTH directly causes these changes. However, the sample size appears relatively small, and the findings are from patients with a rare condition, so results may not apply to everyone. The study is recent (2026) and represents new science that will need confirmation from other research groups.
What the Results Show
The main discovery is that parathyroid hormone activates a previously unknown type of bone remodeling that happens inside the bone structure itself. After 6 months of PTH treatment, the internal porosity (number of tiny tunnels) increased 18-fold compared to patients on standard treatment. After 30 months, this increased to a 36-fold increase. This means bones were developing extensive tunnel networks inside their framework.
When researchers examined the bone samples in detail, they found that in PTH-treated patients, about 7.7% of the internal pores were actively being broken down (eroded), 69.1% were areas where bone was being both broken down and rebuilt simultaneously, 12.9% were areas where new bone was being formed, and only 0.9% were inactive. In contrast, patients on standard treatment alone had almost no internal tunneling activity—81.2% of their bone pores were inactive.
Importantly, when patients stopped taking PTH, their bone remodeling returned to normal levels similar to patients who never received PTH. This reversibility proves that PTH directly controls this process. The internal tunneling mainly occurred in the flat plates and junction areas of the bone structure, not in the rod-like portions, suggesting the process targets specific architectural features.
The study found that internal bone remodeling correlated positively with bone mineralization (the amount of mineral content in bone), suggesting that despite the tunneling, bones were still gaining mineral density. Interestingly, patients taking higher doses of active vitamin D (a common treatment for low parathyroid hormone) showed less internal tunneling, indicating that vitamin D may suppress this PTH-driven remodeling process. The research also demonstrated that this internal remodeling occurs naturally at low levels in healthy people across different ages and bone locations, suggesting it’s a normal physiological process that PTH simply amplifies.
Previous research has documented tunnel-like structures inside bones in patients with kidney disease and those receiving PTH treatment, but scientists didn’t understand what these structures meant or why they formed. This study is the first to systematically describe this as a distinct and important mode of bone remodeling. It parallels the well-known process of intracortical remodeling (tunneling in the dense outer bone), but occurs in the trabecular bone (the spongy inner bone). By providing clear definitions, measurements, and mechanisms, this research transforms observations that were previously considered oddities into recognized physiological processes.
The study focused on patients with hypoparathyroidism, a rare condition, so findings may not directly apply to people with normal parathyroid hormone levels or other bone diseases. The exact sample size isn’t specified in the abstract, though the study appears to involve fewer than 100 participants. While the research used advanced imaging and animal models, it’s primarily observational in nature—researchers measured what happened but couldn’t directly test whether the internal tunneling is beneficial or harmful. The study doesn’t yet explain whether this internal remodeling improves bone strength or increases fracture risk, which is crucial for clinical applications. Additionally, the findings are very recent and haven’t yet been confirmed by independent research groups.
The Bottom Line
For patients with hypoparathyroidism receiving PTH treatment: This research suggests PTH works through a newly understood mechanism, but current treatment decisions should remain unchanged until further research clarifies whether internal bone tunneling improves or worsens bone health. For the general population: No changes to current bone health practices are recommended based on this research alone. For researchers and doctors: This discovery opens new avenues for understanding bone diseases and may eventually lead to improved treatments, but more research is needed to determine clinical significance.
This research is most relevant to patients with hypoparathyroidism or kidney disease (conditions involving PTH abnormalities), people with osteoporosis or other bone disorders, and healthcare providers treating these conditions. It’s less immediately relevant to people with normal bone health, though the fundamental discovery about how bones repair themselves could eventually benefit everyone. Researchers studying bone biology and pharmaceutical companies developing bone-related treatments should pay close attention to these findings.
The changes in bone structure appeared within 6 months of PTH treatment and continued progressing over 30 months. However, this research doesn’t yet clarify how long it takes for these internal changes to affect overall bone strength or fracture risk. Patients shouldn’t expect to feel or notice these microscopic changes—they’re only visible through specialized bone biopsies and imaging. Reversibility occurred after stopping treatment, though the exact timeline for normalization isn’t specified.
Frequently Asked Questions
What is intratrabecular bone remodeling and why is it important?
Intratrabecular remodeling is a newly recognized process where bones develop tunnel-like structures inside their spongy framework. It’s important because it allows bones to repair old and damaged material deep inside that surface-level remodeling can’t reach, potentially improving bone quality and strength.
Does parathyroid hormone treatment strengthen bones or weaken them?
This study shows PTH creates internal tunneling and increases porosity, but doesn’t yet clarify whether this strengthens or weakens bones overall. The internal remodeling correlated with increased bone mineralization, suggesting complexity in how PTH affects bone health. More research is needed to determine clinical outcomes.
Can I see or feel these internal bone changes from PTH treatment?
No, internal bone remodeling happens at a microscopic level and cannot be felt or seen without specialized medical imaging like bone biopsies or advanced CT scans. You won’t notice symptoms from these structural changes, though your doctor can monitor them through imaging.
What happens to bones if you stop taking parathyroid hormone?
When patients in this study stopped PTH treatment, their internal bone remodeling reversed and returned to normal levels within the study period. This shows the process is reversible and directly controlled by PTH, not permanent.
Does vitamin D affect how parathyroid hormone changes bones?
According to this research, higher doses of active vitamin D supplementation correlated with less internal bone tunneling in PTH-treated patients, suggesting vitamin D may suppress this remodeling process. The interaction between these treatments deserves further investigation.
Want to Apply This Research?
- Users receiving PTH treatment could track bone-related symptoms (joint pain, bone pain, fracture history) and treatment adherence (injection dates and doses) to correlate with any clinical changes. While internal bone remodeling isn’t visible without medical imaging, tracking these observable factors helps users and doctors monitor overall bone health.
- Users on PTH therapy should maintain consistent injection schedules and regular follow-up appointments with their healthcare provider, including periodic bone density scans. The app could send reminders for injections and upcoming bone health assessments, helping users stay engaged with their treatment plan.
- Long-term tracking should include: (1) adherence to PTH or other bone-related medications, (2) vitamin D supplementation doses (since the study suggests vitamin D affects internal remodeling), (3) bone pain or fracture incidents, (4) results from bone density scans or other imaging, and (5) lab values for calcium and phosphorus levels. This comprehensive approach helps users and doctors understand how treatment is working over months and years.
This research describes a newly discovered bone remodeling mechanism in patients with hypoparathyroidism. The clinical significance of internal bone tunneling—whether it improves or impairs bone strength and fracture risk—has not yet been established. Patients with hypoparathyroidism or those considering PTH treatment should discuss these findings with their endocrinologist or bone specialist, as current treatment recommendations remain unchanged pending further research. This article is for educational purposes and should not replace professional medical advice. Do not start, stop, or change any bone-related medications without consulting your healthcare provider.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.